Gac Med Mex
-
Mental disorders are one of the main causes of years lived with disability, although there is a lack of recent estimates of their magnitude. ⋯ Mental disorders have considerably increased since the only national mental health survey that used diagnostic criteria to evaluate their prevalence. It is important to invest in epidemiological studies, prevention and care of mental disorders, which are among the leading causes of years lived with disability in the country.
-
Respiratory diseases (RD) are often analyzed separately rather than collectively, possibly leading to an underestimation of their total burden. ⋯ The significant burden of mortality and disability due to RDs in Mexico underscores the n|ecessity for enhanced prevention, research, and for addressing risk factors such as smoking and pollution. Ongoing healthcare training can help reduce RD burden.
-
Mexico faces a challenge due to the burden imposed by type 2 diabetes (T2D). ⋯ Comprehensive policies are urgently needed in order to reduce the burden of T2D in Mexico, through standardized guidelines, evidence-based strategies and technological resources that improve medical care accessibility and efficiency.
-
Previous analyses on the burden of disease in Mexico identified that injuries differentially affect young people, males and working-age people. ⋯ Injuries generate catastrophic consequences in terms of mortality and disability in Mexico. It is necessary to promote and strengthen programs and policies in order to improve the data system and injury prevention.
-
Chronic kidney disease (CKD) represents a substantial global burden of disease due to a lack of universal tests and misinterpretation of biomarkers. ⋯ CKD in Mexico entails a high burden of mortality and years of life lost, but it barely contributes to disability. It is essential to improve CKD early detection, access to treatments and coding of the causes of the disease. Moreover, investigating the causes of CKD of unknown etiology, including genetic factors, is crucial in order for specific treatments to be developed in the future.